Lung Transplant Recipient with Pulmonary Alveolar Proteinosis

Abstract

Pulmonary alveolar proteinosis (PAP) is a progressive lung disease characterized by accumulated surfactant-like lipoproteinaceous material in the alveoli and distal bronchioles. This accumulation is the result of impaired clearance by alveolar macrophages. PAP has been described in 11 solid organ transplant recipients, 9 of whom were treated with mammalian target of rapamycin inhibitors. We report a case of a lung transplant recipient treated with prednisone, mycophenolate mofetil (MMF), and tacrolimus who ultimately developed PAP, which worsened when MMF was replaced with everolimus.

DOI: 10.1155/2016/4628354

Extracted Key Phrases

4 Figures and Tables

Cite this paper

@inproceedings{Tokman2016LungTR, title={Lung Transplant Recipient with Pulmonary Alveolar Proteinosis}, author={Sofya Tokman and Miriam Hahn and Hesham Abdelrazek and Tanmay S Panchabhai and Vipul J Patel and Rajat Walia and Ashraf Omar}, booktitle={Case reports in transplantation}, year={2016} }